What Abbott's FY2025 10-K says: 12 signals
Abbott filed its latest 10-K with the SEC on Feb 20, 2026. It discusses acquisition announced, capex increase and compliance burden.
Public (ABT)Software Development10,000+ employeesabbott.comLinkedIn
- Filed
- Feb 20, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Abbott's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
This major strategic expansion into the cancer diagnostics market will require significant integration efforts, resources, and IT systems consolidation.
$20B
borrowings to fund the Exact Sciences acquisition
cancer diagnostics
Abbott to incur $20B in debt to fund acquisition of Exact Sciences
Abbott plans to fund its acquisition of Exact Sciences with $20 billion in new borrowings, significantly increasing its consolidated debt from $12.9 billion.
$20B
New borrowings to fund Exact Sciences acquisition
Abbott references 2022 infant formula recall and FDA consent decree at Sturgis facility
The filing highlights the major 2022 voluntary recall of infant formula from its Sturgis, Michigan plant and the subsequent consent decree with the FDA.
Entered into FDA consent decree following major infant formula recall
A voluntary recall of infant formula from the Sturgis, Michigan facility led to an FDA consent decree.
Experienced temporary manufacturing stoppage at Sturgis, MI infant formula facility
A production halt at a key facility, tied to a major product recall, highlights potential operational vulnerabilities.
Developing new business models to support data-driven healthcare solutions
Abbott is actively creating new operating models for data-centric strategies, including products with data insights, connectivity, and data management.
informatics
Expanding into cancer diagnostics market through major acquisition
The planned acquisition of Exact Sciences marks Abbott's strategic entry into the cancer diagnostics market.
cancer diagnostics
Global supply chain challenges have adversely impacted cost and availability of materials
The company's complex global supply chain has been negatively affected by inflationary pressures and labor shortages, leading to increased costs and reduced availability of raw materials and services.
Abbott cites significant costs and resources required for regulatory compliance
The company states that adhering to complex FDA and international regulations is a costly and time-consuming process.
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Abbott with the Signal API
One POST /v1/companies/enrich call with abbott.com returns Abbott 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbott.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Abbott 10-K
When did Abbott file its latest 10-K?
What does Abbott's latest 10-K say about acquisition announced?
Where can I find Abbott's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .